AEterna Zentaris to Present at Two Upcoming Conferences in the United States and Germany
October 20 2004 - 8:31AM
PR Newswire (US)
AEterna Zentaris to Present at Two Upcoming Conferences in the
United States and Germany QUEBEC CITY, Canada, Oct. 20
/PRNewswire-FirstCall/ -- AEterna Zentaris Inc. (TSX: AEZ; Nasdaq:
AEZS) today announced that Gilles Gagnon, President and Chief
Executive Officer of the Company, will present a corporate update
at the Rodman & Renshaw Techvest 6th Annual Healthcare
Conference on Wednesday, October 27, 2004, at 3:30 p.m. ET, at the
Waldorf-Astoria Hotel in New York City. A live webcast of the
presentation will be available at
http://www.aeternazentaris.com/en/page.php?p(equal sign)56
Furthermore, on Tuesday, November 9, 2004, at 9:15 a.m. ET, (3:15
p.m. Cologne, Germany), Michel Cousineau, Director, Business
Development at AEterna Zentaris, will present a corporate update at
Bio Europe which will be held in Cologne, Germany from November
8-10, 2004. About AEterna Zentaris Inc. AEterna Zentaris Inc. is a
biopharmaceutical company focused in oncology and endocrine
therapy. Its extensive portfolio, from drug discovery to marketed
products, includes perifosine, an orally-active AKT inhibitor in
several Phase II trials for multiple cancers, and cetrorelix, an
LHRH antagonist already marketed for in vitro fertilization under
the brand name Cetrotide(R), and also in advanced clinical
development for the treatment of uterine myoma, endometriosis and
benign prostatic hyperplasia (BPH). AEterna Zentaris also owns 62%
of Atrium Biotechnologies Inc., which develops, manufactures and
markets active ingredients, specialty fine chemicals, cosmetic and
nutritional products for the cosmetics, chemical, pharmaceutical
and nutritional industries. News releases and additional
information about AEterna Zentaris are available on its new Web
site http://www.aeternazentaris.com/ . Forward-Looking Statements
This press release contains forward-looking statements made
pursuant to the safe harbor provisions of the U.S. Securities
Litigation Reform Act of 1995. Forward-looking statements involve
known and unknown risks and uncertainties, which could cause the
Company's actual results to differ materially from those in the
forward-looking statements. Such risks and uncertainties include,
among others, the availability of funds and resources to pursue
R&D projects, the successful and timely completion of clinical
studies, the ability of the Company to take advantage of business
opportunities in the pharmaceutical industry, uncertainties related
to the regulatory process and general changes in economic
conditions. Investors should consult the Company's quarterly and
annual filings with the Canadian and U.S. securities commissions
for additional information on risks and uncertainties relating to
the forward-looking statements. Investors are cautioned not to rely
on these forward-looking statements. The Company does not undertake
to update these forward- looking statements. DATASOURCE: AETERNA
ZENTARIS INC. (FORMERLY/ANCIENNEMENT - LES LABORATOIRES AETERNA
CONTACT: Media Relations: Paul Burroughs, (418) 652-8525, ext. 406,
; U.S. Investor Relations: Lippert/Heilshorn & Associates, Kim
Golodetz, (212) 838-3777, ; Investor Relations: Jacques Raymond,
(418) 652-8525, ext. 360, ; Europe: Matthias Seeber, +49 69 42602
3425, ; To request a free copy of this organization's annual
report, please go to http://www.newswire.ca/ and click on
reports@cnw.
Copyright